March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Suppression of Retinal Expression of Indoleamine 2,3-Dioxygenase (IDO) in Experimental and Human Diabetes
Author Affiliations & Notes
  • Babak Baban
    Oral Biology,
    Georgia Health Sciences University, Augusta, Georgia
  • Folami Lamoke
    Pharmacology and Toxicology,
    Georgia Health Sciences University, Augusta, Georgia
  • Jun Yao Liu
    Oral Biology,
    Georgia Health Sciences University, Augusta, Georgia
  • Mahmood Mozaffari
    Oral Biology,
    Georgia Health Sciences University, Augusta, Georgia
  • Manuela Bartoli
    Ophthalmology,
    Georgia Health Sciences University, Augusta, Georgia
  • Footnotes
    Commercial Relationships  Babak Baban, None; Folami Lamoke, None; Jun Yao Liu, None; Mahmood Mozaffari, None; Manuela Bartoli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5406. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Babak Baban, Folami Lamoke, Jun Yao Liu, Mahmood Mozaffari, Manuela Bartoli; Suppression of Retinal Expression of Indoleamine 2,3-Dioxygenase (IDO) in Experimental and Human Diabetes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5406.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The enzyme indoleamine 2,3-dioxygenase (IDO) belongs to the family of heme-containing oxidoreductases and is involved in tryptophan metabolism. Besides its well documented activity in regulating the maturation and recruitment of regulatory T-cells, tissue-specific expression of IDO during inflammation represents a self-protection mechanism to limit antigen-specific immune responses. Previous studies have shown that IDO is expressed in the retina and its expression varies in response to acute inflammatory stimuli. Diabetic retinopathy, DR, is thought to involve chronic sub-clinical inflammation. Here we wanted to determine whether expression of IDO is altered in the diabetic retina.

Methods: : Db/db mice, a model of type 2 diabetes, were sacrificed at 12-14 weeks of age. Human post-mortem retinas from diabetic and non diabetic donors, were obtained from Georgia Eye Bank. Western blotting and immunoistochemical analyses were conducted to determine IDO expression in the murine and human diabetic retina and compared to non diabetic controls.

Results: : Immunohistochemical and Western blotting analyses showed that IDO expression was significantly reduced in db/db mice (p<0.05 versus control, n=8) as compared to age-matched normoglycemic control animals (n=8). In the post-mortem human diabetic retinas (n=6) we have also found a marked reduction of IDO expression compared to non diabetic donors (p<0.05, n=6).

Conclusions: : Our data demonstrate, for the first time, that the immunomodulator IDO is down-regulated in the diabetic retina (murine and human), thus potentially implicating its function in maintenance of retinal anti-inflammatory protective mechanisms. The obtained results, therefore, warrant further studies to understand the mechanisms of hyperglycemia-induced downregulation of IDO and its significance in the pathogenesis of DR.

Keywords: diabetic retinopathy • inflammation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×